Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Permanent Puerto Rico tax credit

This article was originally published in The Gray Sheet

Executive Summary

Permanent Puerto Rico tax credit: Targeted wage-based credit for companies doing business in Puerto Rico would be made permanent unless certain economic goals were met under legislation (S 906) introduced June 16 by Sens. Alfonse D'Amato (R-N.Y.), John Chafee (R-R.I.), John Breaux (D-La.), Orrin Hatch (R-Utah) and Bob Graham (D-Fla.). Sec. 30a of the tax code would also be expanded to cover companies seeking to locate or expand their activities in Puerto Rico. Sec. 30a was established in the 104th Congress' phase-out of the Sec. 936 tax credit for economic activities in Puerto Rico and other territories that limited the credit to companies already claiming wage-based 936 credit. Both wage-based and income-based credits would be eliminated after Jan. 1, 2006 under current law...

You may also be interested in...



Executives On The Move: CEOs Named At Elevation Oncology, PainReform Ltd

Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma

Viatris Kickstarts Business With Tentative Approval For Pediatric Dolutegravir

The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program. 

J&J Leverages Power Of Digital Personalization With Nicorette UK Extension

Johnson & Johnson believes personalization via digital holds the key to smoking cessation success as it launches in the UK its app-supported Nicorette QuickMist SmartTrack product.

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel